IPD Shares ImpediMed Limited
ASX · ASXLast in our picks 2026-10-03 — not in the current list; analysis below is from that screen
Commercial turnaround candidate with strong re-rating potential from execution.
Signal breakdown
- ▸Speculative buying interest, but execution remains critical.
- ▸Above 50-day MA (+19.52%)
- ▸Volume 1.73× average — accumulation
- ▾Near 52-week low (5.8% of range)
Is IPD a buy right now?
Trend: IPD is trading below the 50-day average (-60.00%), RSI 58 — neutral momentum, with a 3-month return of +0.00%.
Valuation & quality: ImpediMed Limited trades on forward P/E -2.2, price-to-book 1.33; fundamentals show net margin -170.4%, return on equity -162.4%, revenue growth 5.7% year on year.
Analyst consensus: 4 analysts have a mean 12-month price target of A$0.02 (+422.8% vs the last close; range A$0.01 – A$0.04), consensus rating “none”.
Our screen: BUY (score 2) — Commercial turnaround candidate with strong re-rating potential from execution.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +0.00% | -50.00% | +0.00% | -100.00% | — | — | — | — |
Fundamentals
Analyst price target
Technical signals
About ImpediMed Limited
ImpediMed Limited, a medical technology company, engages in the development, manufacture, and sale of bioimpedance spectroscopy (BIS) systems and software services in Australia, Europe, North America, and internationally.
Sector: Healthcare · Industry: Medical Devices · United States · 66 employees · Website
Related Health Care picks
Browse: all ASX stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.